Clinical trial
Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute…
NCT00296192 · UCB Pharma, Industry · Completed
Key facts
| NCT number | NCT00296192 |
|---|---|
| Title | Efficacy, Safety and Tolerability of Rotigotine Nasal Spray for the Acute Treatment of Parkinson Symptoms |
| Official title | A Double-Blind, Placebo-Controlled, Parallel-Group, Proof of Concept Trial to Assess the Tolerability, Safety, and Efficacy of Rotigotine Nasal Spray for the Acute Treatment of "OFF" Symptoms in Subjects With Advanced-Stage, Idiopathic Parkinson Disease |
| Lead sponsor | UCB Pharma, Industry |
| Status | Completed |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Parkinson's Disease |
| Intervention type | Drug, Other |
| Interventions | Rotigotine nasal spray, Placebo |
| Enrollment | 82 |
| Start date | Feb 1, 2006 |
| Primary completion | Jun 1, 2006 |
| Completion | Jun 1, 2006 |
| First posted | Feb 24, 2006 |
| Last update posted | Oct 2, 2014 |
At a glance
- Yes Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: